FCRL4 and neoplasm: The data suggest that in the TME of immunotherapy responders, FCRL4+ FCRL5+ B cells are driven by IFNα, TNF, and IL27 signals, and Tfhs are activated by these B cells to enhance anti-tumor immunity through secreting IL21.